Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Harvard Business School
McKesson
Baxter
Moodys

Last Updated: August 11, 2022

Investigational Drug Information for QPI-1002


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for QPI-1002?

QPI-1002 is an investigational drug.

There have been 8 clinical trials for QPI-1002. The most recent clinical trial was a Phase 3 trial, which was initiated on June 29th 2018.

The most common disease conditions in clinical trials are Wounds and Injuries, Optic Neuropathy, Ischemic, and Optic Nerve Diseases. The leading clinical trial sponsors are Quark Pharmaceuticals and [disabled in preview].

There are two US patents protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for QPI-1002
TitleSponsorPhase
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac SurgeryQuark PharmaceuticalsPhase 3
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney TransplantQuark PharmaceuticalsPhase 3
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)Quark PharmaceuticalsPhase 2/Phase 3

See all QPI-1002 clinical trials

Clinical Trial Summary for QPI-1002

Top disease conditions for QPI-1002
Top clinical trial sponsors for QPI-1002

See all QPI-1002 clinical trials

US Patents for QPI-1002

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
QPI-1002 See Plans and Pricing Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
QPI-1002 See Plans and Pricing Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for QPI-1002

Drugname Country Document Number Estimated Expiration Related US Patent
QPI-1002 Argentina AR108097 2036-04-04 See Plans and Pricing
QPI-1002 Australia AU2017246228 2036-04-04 See Plans and Pricing
QPI-1002 Brazil BR112018070214 2036-04-04 See Plans and Pricing
QPI-1002 Canada CA3019137 2036-04-04 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Harvard Business School
McKesson
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.